538 related articles for article (PubMed ID: 36990308)
21. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
Holme AM; Roland MC; Henriksen T; Michelsen TM
Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
[TBL] [Abstract][Full Text] [Related]
22. Angiogenic and fibrinolytic factors in blood during the first half of pregnancy and adverse pregnancy outcomes.
Coolman M; Timmermans S; de Groot CJ; Russcher H; Lindemans J; Hofman A; Geurts-Moespot AJ; Sweep FC; Jaddoe VV; Steegers EA
Obstet Gynecol; 2012 Jun; 119(6):1190-200. PubMed ID: 22617584
[TBL] [Abstract][Full Text] [Related]
23. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation.
Tsiakkas A; Saiid Y; Wright A; Wright D; Nicolaides KH
Am J Obstet Gynecol; 2016 Jul; 215(1):87.e1-87.e17. PubMed ID: 26875953
[TBL] [Abstract][Full Text] [Related]
24. Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy.
Park HJ; Kim SH; Jung YW; Shim SS; Kim JY; Cho YK; Farina A; Zanello M; Lee KJ; Cha DH
BMC Pregnancy Childbirth; 2014 Jan; 14():35. PubMed ID: 24444293
[TBL] [Abstract][Full Text] [Related]
25. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
Poon LC; Shennan A; Hyett JA; Kapur A; Hadar E; Divakar H; McAuliffe F; da Silva Costa F; von Dadelszen P; McIntyre HD; Kihara AB; Di Renzo GC; Romero R; D'Alton M; Berghella V; Nicolaides KH; Hod M
Int J Gynaecol Obstet; 2019 May; 145 Suppl 1(Suppl 1):1-33. PubMed ID: 31111484
[TBL] [Abstract][Full Text] [Related]
26. Validation and development of models using clinical, biochemical and ultrasound markers for predicting pre-eclampsia: an individual participant data meta-analysis.
Allotey J; Snell KI; Smuk M; Hooper R; Chan CL; Ahmed A; Chappell LC; von Dadelszen P; Dodds J; Green M; Kenny L; Khalil A; Khan KS; Mol BW; Myers J; Poston L; Thilaganathan B; Staff AC; Smith GC; Ganzevoort W; Laivuori H; Odibo AO; Ramírez JA; Kingdom J; Daskalakis G; Farrar D; Baschat AA; Seed PT; Prefumo F; da Silva Costa F; Groen H; Audibert F; Masse J; Skråstad RB; Salvesen KÅ; Haavaldsen C; Nagata C; Rumbold AR; Heinonen S; Askie LM; Smits LJ; Vinter CA; Magnus PM; Eero K; Villa PM; Jenum AK; Andersen LB; Norman JE; Ohkuchi A; Eskild A; Bhattacharya S; McAuliffe FM; Galindo A; Herraiz I; Carbillon L; Klipstein-Grobusch K; Yeo S; Teede HJ; Browne JL; Moons KG; Riley RD; Thangaratinam S
Health Technol Assess; 2020 Dec; 24(72):1-252. PubMed ID: 33336645
[TBL] [Abstract][Full Text] [Related]
27. Ophthalmic artery Doppler in combination with other biomarkers in prediction of pre-eclampsia at 35-37 weeks' gestation.
Sarno M; Wright A; Vieira N; Sapantzoglou I; Charakida M; Nicolaides KH
Ultrasound Obstet Gynecol; 2021 Apr; 57(4):600-606. PubMed ID: 33073902
[TBL] [Abstract][Full Text] [Related]
28. Midgestation maternal serum 25-hydroxyvitamin D level and soluble fms-like tyrosine kinase 1/placental growth factor ratio as predictors of severe preeclampsia.
Woodham PC; Brittain JE; Baker AM; Long DL; Haeri S; Camargo CA; Boggess KA; Stuebe AM
Hypertension; 2011 Dec; 58(6):1120-5. PubMed ID: 21986503
[TBL] [Abstract][Full Text] [Related]
29. Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population.
Chaemsaithong P; Pooh RK; Zheng M; Ma R; Chaiyasit N; Tokunaka M; Shaw SW; Seshadri S; Choolani M; Wataganara T; Yeo GSH; Wright A; Leung WC; Sekizawa A; Hu Y; Naruse K; Saito S; Sahota D; Leung TY; Poon LC
Am J Obstet Gynecol; 2019 Dec; 221(6):650.e1-650.e16. PubMed ID: 31589866
[TBL] [Abstract][Full Text] [Related]
30. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N
Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323
[TBL] [Abstract][Full Text] [Related]
31. Real-world data on the clinical use of angiogenic factors in pregnancies with placental dysfunction.
Dathan-Stumpf A; Czarnowsky V; Hein V; Andraczek T; Stepan H
Am J Obstet Gynecol; 2022 Feb; 226(2S):S1037-S1047.e2. PubMed ID: 33892922
[TBL] [Abstract][Full Text] [Related]
32. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis.
Frampton GK; Jones J; Rose M; Payne L
Health Technol Assess; 2016 Nov; 20(87):1-160. PubMed ID: 27918253
[TBL] [Abstract][Full Text] [Related]
33. Correlation of sFlt/PlGF ratio with severity of preeclampsia in an Indian population.
Kumar N; Das V; Agarwal A; Agrawal S
AJOG Glob Rep; 2023 May; 3(2):100177. PubMed ID: 36911235
[TBL] [Abstract][Full Text] [Related]
34. STATIN trial: predictive performance of competing-risks model in screening for pre-eclampsia at 35-37 weeks' gestation.
Döbert M; Wright A; Varouxaki AN; Mu AC; Syngelaki A; Rehal A; Delgado JL; Akolekar R; Muscettola G; Janga D; Singh M; Martin-Alonso R; Dütemeyer V; De Alvarado M; Atanasova V; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2022 Jan; 59(1):69-75. PubMed ID: 34580947
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population.
Kienast C; Moya W; Rodriguez O; Jijón A; Geipel A
J Matern Fetal Neonatal Med; 2016; 29(4):537-43. PubMed ID: 25708492
[TBL] [Abstract][Full Text] [Related]
36. Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia: The Angiogenic-Placental Syndrome.
Stepan H; Hund M; Andraczek T
Hypertension; 2020 Apr; 75(4):918-926. PubMed ID: 32063058
[TBL] [Abstract][Full Text] [Related]
37. Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35-37 weeks' gestation.
Ciobanu A; Rouvali A; Syngelaki A; Akolekar R; Nicolaides KH
Am J Obstet Gynecol; 2019 May; 220(5):486.e1-486.e11. PubMed ID: 30707967
[TBL] [Abstract][Full Text] [Related]
38. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
Gallo DM; Wright D; Casanova C; Campanero M; Nicolaides KH
Am J Obstet Gynecol; 2016 May; 214(5):619.e1-619.e17. PubMed ID: 26627730
[TBL] [Abstract][Full Text] [Related]
39. Novel circulating placental markers prokineticin-1, soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor and association with late miscarriage.
Jayasena CN; Abbara A; Comninos AN; Narayanaswamy S; Gonzalez Maffe J; Izzi-Engbeaya C; Oldham J; Lee TT; Sarang Z; Malik Z; Dhanjal MK; Williamson C; Regan L; Bloom SR; Dhillo WS
Hum Reprod; 2016 Dec; 31(12):2681-2688. PubMed ID: 27664209
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous Women.
Sovio U; Gaccioli F; Cook E; Hund M; Charnock-Jones DS; Smith GC
Hypertension; 2017 Apr; 69(4):731-738. PubMed ID: 28167687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
